pSivida Corp

Investor Relations Home

pSivida develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. We have developed three of the four products approved in either the U.S. or the EU for sustained release delivery of drug to treat chronic back-of-the-eye diseases utilizing multiple generations of our Durasert technology system.

Our lead development product, ILUVIEN® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology.The US Food and Drug Administration (FDA) approved ILUVIEN for the treatment of diabetic macular edema (DME) for patients treated with a course of corticosteroids and did not have a significant rise in intraocular pressure (IOP). ILUVIEN is marketed in the U.K., Germany and Portugal and has or is pending marketing autorization in 14 other EU countries.
 

pSivida’s other two FDA-approved products, Retisert® and Vitrasert®, licensed to Bausch & Lomb, Inc., are implants utilizing earlier generations of our Durasert technology system that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.

View all »   RSS

Recent Releases

Sep 3, 2015
pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation's BioInterface 2015 Annual Symposium

Sep 2, 2015
pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information

View all »

Events & Presentations

Sep 9, 2015 at 4:30 PM ET
Q4 2015 pSivida Corp. Earnings Conference Call


IR Contacts

Beverly Jedynak
President
Martin E. Janis & Company
Phone: 312-943-1123
bjedynak@janispr.com

Transfer Agent:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940 USA
Phone: 781-575-2879
Fax: 781-575-3605

 
pSivida